Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer

To see complete record on, please visit this link

Id: NCT05398484

Organisation Name: NYU Langone Health

Overal Status: Not yet recruiting

Start Date: November 1, 2022

Last Update: September 16, 2022

Lead Sponsor: NYU Langone Health

Brief Summary: The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose psilocybin 1mg) in the treatment of anxiety, depression, and existential distress (i.e. loss of meaning and hope; fear of death) in advanced cancer (i.e. stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression and existential distress in advanced cancer.

  • Advanced Cancer

Total execution time in seconds: 0.20293784141541